Zevra Therapeutics, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits
Zevra Therapeutics, Inc. (ZVRA) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits of $715.00 thousand as of 2016-12-31, per its 10-K filed 2017-03-10.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits · last filed 2017-03-10
- 2016-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $715.00K.
- 2015-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $232.00K.
- 2014-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $83.00K.
- 2013-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $76.00K.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits |
|---|---|
| 2016-12-31 | $715.00K 10-K · filed 2017-03-10 |
| 2015-12-31 | $232.00K 10-K · filed 2017-03-10 |
| 2014-12-31 | $83.00K 10-K · filed 2017-03-10 |
| 2013-12-31 | $76.00K 10-K · filed 2016-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |